Corsair Capital Management L.P. Takes Position in Halozyme Therapeutics, Inc. $HALO

Corsair Capital Management L.P. acquired a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the first quarter, Holdings Channel reports. The institutional investor acquired 10,000 shares of the biopharmaceutical company’s stock, valued at approximately $646,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Empowered Funds LLC bought a new stake in Halozyme Therapeutics in the first quarter valued at approximately $755,000. Acadian Asset Management LLC bought a new position in Halozyme Therapeutics during the 1st quarter worth approximately $195,000. Hsbc Holdings PLC raised its holdings in Halozyme Therapeutics by 117.1% during the 2nd quarter. Hsbc Holdings PLC now owns 10,102 shares of the biopharmaceutical company’s stock worth $522,000 after purchasing an additional 5,448 shares during the last quarter. EverSource Wealth Advisors LLC lifted its position in shares of Halozyme Therapeutics by 6.9% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company’s stock worth $140,000 after purchasing an additional 174 shares during the period. Finally, Baird Financial Group Inc. lifted its position in shares of Halozyme Therapeutics by 6.2% in the 2nd quarter. Baird Financial Group Inc. now owns 11,090 shares of the biopharmaceutical company’s stock worth $577,000 after purchasing an additional 650 shares during the period. 97.79% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Halozyme Therapeutics

In related news, Director Bernadette Connaughton sold 1,625 shares of the company’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $76.71, for a total value of $124,653.75. Following the sale, the director owned 42,044 shares in the company, valued at $3,225,195.24. This represents a 3.72% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mahesh Krishnan sold 7,304 shares of the company’s stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $75.00, for a total transaction of $547,800.00. Following the completion of the sale, the director owned 14,462 shares in the company, valued at $1,084,650. This represents a 33.56% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 74,102 shares of company stock valued at $5,205,798 over the last three months. Corporate insiders own 2.50% of the company’s stock.

Halozyme Therapeutics Stock Performance

NASDAQ HALO opened at $81.93 on Monday. The company has a market cap of $9.72 billion, a P/E ratio of 29.47, a PEG ratio of 0.34 and a beta of 0.84. The company has a fifty day simple moving average of $73.08 and a 200 day simple moving average of $70.58. The company has a current ratio of 2.76, a quick ratio of 2.33 and a debt-to-equity ratio of 8.81. Halozyme Therapeutics, Inc. has a 12-month low of $57.67 and a 12-month high of $82.99.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings data on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share for the quarter, topping the consensus estimate of $1.54 by $0.06. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The firm had revenue of $376.71 million for the quarter, compared to the consensus estimate of $358.60 million. During the same quarter in the prior year, the company posted $1.11 earnings per share. The business’s revenue was up 42.2% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. Sell-side analysts predict that Halozyme Therapeutics, Inc. will post 7.54 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on HALO. Benchmark reiterated a “buy” rating on shares of Halozyme Therapeutics in a research report on Tuesday, July 21st. Wall Street Zen upgraded shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, May 16th. Weiss Ratings raised shares of Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a research report on Tuesday, May 12th. Morgan Stanley decreased their price target on Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a report on Tuesday, May 12th. Finally, UBS Group reissued a “buy” rating and issued a $90.00 price objective on shares of Halozyme Therapeutics in a research report on Wednesday, June 3rd. Eight investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $81.60.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.